Ellipses Pharma explores London listing through Wolfram Resources deal
UK biotech listings have been under pressure as companies seek higher valuations in overseas markets, and Ellipses Pharma is now weighing a public market route in London. The cancer drug developer says it is exploring a transaction with special purpose acquisition company Wolfram Resources and is targeting completion by early 2027.
Highlights
- Ellipses Pharma is exploring a London listing via a reverse takeover by Wolfram Resources, with deal terms yet to be agreed.
- The company targets equity fundraising alongside the transaction and aims to complete the proposed listing by early 2027.
- A successful listing could support London's equity market by retaining growth biotech firms and expanding Ellipses Pharma's investor base amid ongoing cancer drug trials.
Reverse takeover plan and funding timeline
As reported by Reuters, Ellipses Pharma says it is exploring a London listing through a reverse takeover by shell company Wolfram Resources, although the terms of the deal have not yet been agreed.The company, established in 2017, has a pipeline that includes trials for drugs treating non-small cell lung cancer and breast cancer. It plans to list its shares on the London bourse after the proposed transaction and also expects an equity fundraise alongside the deal.
Founder and chair Chris Evans says using a reverse takeover process will enable the company to raise additional capital from public company investors. Ellipses Pharma is targeting completion of the transaction by early 2027.
Potential support for the UK market
The proposed flotation could offer a needed lift for the UK market, which has seen an exodus of companies pursuing higher valuations in markets such as the U.S.For London's equity market, a successful biotech listing would add to efforts to retain growth companies in sectors that typically require repeated access to capital. For Ellipses Pharma, the structure could broaden its investor base as it advances cancer drug development.
Earlier, we outlined the main factors behind SCA Solutions IPO as it sought to raise RM47.85 million on Bursa Malaysia’s ACE Market.